Biosimilar Therapeutic Peptides Market Expected to Reach $4.87 Billion by 2028

Overview and Scope Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses. Sizing and Forecast The biosimilar therapeutic peptides market size has grown exponentially in recent years. It will grow from $2.06 billion in 2023 to $2.68 billion in 2024 at a compound annual growth rate (CAGR) of 30.3%. The growth in the historic period can be attributed to increasing demand for cost-effective therapeutics, regulatory support and frameworks, patent expirations of biologic drugs, rising incidence of chronic diseases, established manufacturing processes. The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $4.87 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expanding therapeutic applications, global aging population, market competitiveness, strategic collaborations and partnerships, patient preference for non-invasive therapies. Major trends in the forecast period include advancements in biotechnology, increasing demand for biologics, technological innovations in manufacturing, focus on cost-efficiency and access to healthcare, technological advancements. Order your report now for swift delivery, visit the link: https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report The biosimilar therapeutic peptides market covered in this report is segmented – 1) By Type: Innovative, Generic 2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations 3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders North America was the largest region in the biosimilar therapeutics market in 2023. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. Intrigued to explore the contents? Secure your hands-on a free sample copy of the report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp Major Driver Impacting Market Growth The increasing ageing population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides’ market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the growth of biosimilar market. Key Industry Players Major companies operating in the biosimilar therapeutic peptides market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., Hyperion Therapeutics Inc., BioPartners Inc., Samsung Bioepis Co. Ltd. The biosimilar therapeutic peptides market report table of contents includes: 1. Executive Summary 2. Biosimilar Therapeutic Peptides Market Characteristics 3. Biosimilar Therapeutic Peptides Market Trends And Strategies 4. Biosimilar Therapeutic Peptides Market - Macro Economic Scenario ............. 32. Global Biosimilar Therapeutic Peptides Market Competitive Benchmarking 33. Global Biosimilar Therapeutic Peptides Market Competitive Dashboard 34. Key Mergers And Acquisitions In The Biosimilar Therapeutic Peptides Market 35. Biosimilar Therapeutic Peptides Market Future Outlook and Potential Analysis 36. Appendix Contact Us: The Business Research Company Euro